The health service has been advised against funding a treatment for advanced skin cancer.
The National Centre for Pharmacoeconomics (NCPE), which carries out cost-effectiveness studies on new medicines in Ireland, concluded that the drug, Zelboraf, did not represent value for money.
Zelboraf, which is manufactured by Roche, costs €57,000 per year and blocks the effect of a mutation in a gene called BRAF. About half of patients with melanoma have this genetic mutation, which spurs...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team